HARMONi: A New Tune in EGFRm NSCLC?

Results from the phase III HARMONi trial suggest that adding the bispecific ivonescimab to chemotherapy offers a significant improvement in progression-free survival for patients with EGFR-mutated advanced non–small cell lung cancer. However, it is questionable whether the drug’s PD-1 inhibition adds any benefit to its anti-VEGF activity.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0070
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HARMONi: A New Tune in EGFRm NSCLC?

Cancer Discovery
Lung Cancer Treatments and Mutations
article

HARMONi: A New Tune in EGFRm NSCLC?

article en

Abstract

Results from the phase III HARMONi trial suggest that adding the bispecific ivonescimab to chemotherapy offers a significant improvement in progression-free survival for patients with EGFR-mutated advanced non–small cell lung cancer. However, it is questionable whether the drug’s PD-1 inhibition adds any benefit to its anti-VEGF activity.

Cancer Discovery
Openalex Percentile: Top 64%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HARMONi: A New Tune in EGFRm NSCLC? · Cancer Discovery (2025) | TGRS Research Map | TGRS